HealthcareGenerative AIMachine Learning
Novo Nordisk builds AI drug discovery platform on Azure with Microsoft Research
Novo Nordisk
Novo Nordisk partnered with Microsoft Research to build an AI platform on Azure AI and data stacks spanning regulatory affairs, early research, drug discovery and trial design, using Azure OpenAI Service, Azure Cosmos DB and Azure Kubernetes Service, with Power BI and Power Apps for collaboration. The platform includes a copilot for researchers, shared reasoning-chain templates, and governance/auditing of how data and models are used. The teams published early results on predictive AI models for cardiovascular disease risk detection, including an algorithm that Novo Nordisk says predicts patients' cardiovascular risk better than the best clinical standards, drawing on more than 100 years of insulin research data.
